¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20
±³À°ÀÏÀÚ : 2020-11-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 KALC International Conference      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤ 
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:00~08:40 Tumor Infiltrating Lymphocytes and the Microenvironment as Biomarkers for Lung Cancer  David Rimm(Yale University School of Medicine) 
È޽Ġ11¿ù 20ÀÏ  08:40~08:50 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:50~09:30 Present and Future Perspectives of First-Line Checkpoint Inhibitor for Stage IV Nonsmall Cell Lung Cancer  David Carbone(The Ohio State University) 
È޽Ġ11¿ù 20ÀÏ  09:30~09:40 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:40~10:05 Harms, benefits and cost effectiveness of lc screening  Harry J. de Koning(Erasmus University Medical Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:05~10:30 LDCT Screening in Non-Smokers in Taiwan  Pan-Chyr Yang(National Taiwan University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:30~10:55 Imaging Biomarkers in Lung Cancer Screening  ±¸Áø¸ð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:55~11:20 Liquid Biomarkers in Lung Cancer Screening  À̰迵(°Ç±¹ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  11:20~11:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:30~12:20 Is it time for a paradigm shift in first line treatment of advanced NSCLC?  ±èÇý·Ã(¿¬¼¼ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  12:20~12:40 Break&ÃÑȸ  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:40~13:05 Predictive Biomarkers for Efficacy of Immune Checkpoint Blockades in Lung Cancer  David Carbone(The Ohio State University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:05~13:30 Translation Research in Immunotherapy for Lung Cancer  Hidetoshi Hayashi(Kindai University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:30~13:55 Is HyperProgression Real, or How Do We Prepare for It?  ¼±Á¾¹«(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:55~14:20 If Less Is Good, More Is Better_Combination of ImmunoTx  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  14:20~14:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:30~14:55 Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer  Aaron Hata(Massachusetts General HospitalHarvard Medical School) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:55~15:20 Treatment for Advanced ALK, ROS1-Rearranged Lung Cancer  ±èµ¿¿Ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:20~15:45 Treatment for Advanced MET, RET-Altered Lung Cancer  Yasushi Goto(National Hospital Organization Kyushu Cancer Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:45~16:10 Treatment for Other Minor Mutations-Positive Advanced Lung Cancer  °­ÀºÁÖ(°í·ÁÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  16:10~16:20 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:20~16:45 E-Cigarettes and Vaping-Related Lung Injury  Jay H. Ryu(Mayo Clinic College of Medicine and Science) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:45~17:10 Current Status of Smoking Cessation with Heated Tobacco Products use in Japan  Takahiro Tabuchi(Osaka international Cancer institute) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:10~17:35 Current status of smoking cessation program in Korea and COVID-19 risk in smokers  ÃµÀº¹Ì(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:35~18:00 Pharmacotherapy for Smoking Cessation and Nicotine Dependence  ÃÖÇý¼÷(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇǺΰúÀÇ»çȸ Á¦2ȸ ´ëÀü/¼¼Á¾/Ãæû Çмú ½ÉÆ÷Áö¿ò : 2020-11-21
´ÙÀ½±Û ´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
204 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/06 : 2018-09-06 0 352 2018-07-28
203 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-06 0 512 2018-07-28
202 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø 2018 ¾à¹°ÀÌ»ó¹ÝÀÀ ½ÉÆ÷Áö¾ö : 2018-09-05 0 910 2018-07-28
201 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-05 0 600 2018-07-28
200 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø »ç½Ã Áø·áÀÇ ÇÔÁ¤À» ÇÇÇØ°¡·Á¸é : 2018-09-04 0 1,013 2018-07-28
199 ¼­¿ï Á¦ÀϺ´¿ø 2018 »ý½Ä¹ß»ýµ¶¼º¿¬±¸ ¹× ¸¶´õ¸®½ºÅ©ÇÁ·Î±×·¥ÀÇ ÃֽŰæÇâ : 2018-09-02 0 659 2018-07-28
198 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-02 0 893 2018-07-28
197 ¼­¿ï ´ëÇѺñ¸¸°Ç°­ÇÐȸ 2018 Ãß°èÇмú´ëȸ : 2018-09-02 0 942 2018-07-28
196 ¼­¿ï Á¦3ȸ °æÈñ´ëÇб³º´¿ø ¿°Áõ¼ºÀåÁúȯ¼¾ÅÍ °³¿øÀÇ ¿¬¼ö°­Á -¿°Áõ¼ºÀåÁúȯ Áø·áÀÇ ÃֽŠµ¿Çâ - : 2018-09-02 0 1,474 2018-07-28
195 ´ë±¸ ´ë±¸°¡Å縯´ëÇб³º´¿ø ÀÏÂ÷Áø·á¿¡¼­ ÈçÈ÷ º¸´Â ·ù¸¶Æ¼½ºÁúȯÀÇ °¨º°Áø´Ü ¹× Ä¡·á ¹Ù·Î ¾Ë±â : 2018-09-02 0 897 2018-07-28
194 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇÐȸ Ã߰迬¼ö°­Á : 2018-09-02 0 325 2018-07-28
193 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø ¾È°úÁúȯÀÇ ÃÖ½ÅÁö°ß : 2018-09-02 0 2,242 2018-07-28
192 ¼­¿ï Á¦21ȸ ¼­¿ï¾Æ»êº´¿ø ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-02 0 755 2018-07-28
191 ¼­¿ï »ï¼º¼­¿ïº´¿ø Á¦21ȸ »ï¼º ºÎºñµ¿ ³»½Ã°æ¼ö¼ú ½ÉÆ÷Áö¾ö : 2018-09-02 0 590 2018-07-28
190 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø SNUH 3A(Anesthesiology Alumni Annual)Update : 2018-09-01 0 511 2018-07-28
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷